Mapp Biopharmaceutical, Inc.
We develop novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense.
BARDA partners with Mapp Biopharmaceutical, Inc. to develop next generation therapeutic for Botulinum Neurotoxin
BARDA partners with Mapp Biopharmaceutical, Inc. to develop next generation therapeutic for Botulinum Neurotoxin BARDA...
MappBio Announces Contract with BARDA for MBP091 as a pan-Marburg Medical Countermeasure
MappBio Announces Contract with BARDA for MBP091 as a pan-Marburg Medical...
Experimental antibody ‘cocktail’ protects animals from three deadly Ebola viruses
Public Release

Therapy for Argentine hemorrhagic fever in nonhuman primates with a humanized monoclonal antibody
Larry Zeitlin, Robert W Cross, Joan B Geisbert, Viktoriya Borisevich, Krystle N Agans, Abhishek N Prasad, Sven Enterlein, M Javad Aman, Zachary A Bornholdt, Miles B Brennan, Lioudmila Campbell, Do Kim, Neil Mlakar, Crystal L Moyer, Michael H Pauly, William Shestowsky, Kevin Whaley, Karla A Fenton, Thomas W Geisbert
Proc Natl Acad Sci USA. 2021 Mar 16;118(11):e2023332118. doi: 10.1073/pnas.2023332118.
Passive immunization with an extended half-life monoclonal antibody protects Rhesus macaques against aerosolized ricin toxin
Roy CJ, Van Slyke G, Ehrbar D, Bornholdt ZA, Brennan MB, Campbell L, Chen M, Kim D, Mlakar N, Whaley KJ, Froude JW, Torres-Velez FJ, Vitetta E, Didier PJ, Doyle-Meyers L, Zeitlin L, Mantis NJ. NPJ Vaccines. 2020 Feb 13;5:13. doi: 10.1038/s41541-020-0162-0.